Click for best price
Neuromyelitis Optic Spectrum Disorder Drugs Market Size, Share 2023
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optic Spectrum Disorder Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optic Spectrum Disorder Drugs. This report contains market size and forecasts of Neuromyelitis Optic Spectrum Disorder Drugs in global, including the following market information:
Global Neuromyelitis Optic Spectrum Disorder Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Neuromyelitis Optic Spectrum Disorder Drugs Market Sales, 2018-2023, 2024-2030, (Kiloton)
Global top five Neuromyelitis Optic Spectrum Disorder Drugs companies in 2022 (%)
The global Neuromyelitis Optic Spectrum Disorder Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Glucocorticoids Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Neuromyelitis Optic Spectrum Disorder Drugs include Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork and Baxter, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Neuromyelitis Optic Spectrum Disorder Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neuromyelitis Optic Spectrum Disorder Drugs Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (Kiloton)
Global Neuromyelitis Optic Spectrum Disorder Drugs Market Segment Percentages, by Type, 2022 (%)
Glucocorticoids
Immunotherapies
Other
Global Neuromyelitis Optic Spectrum Disorder Drugs Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (Kiloton)
Global Neuromyelitis Optic Spectrum Disorder Drugs Market Segment Percentages, by Application, 2022 (%)
Acute Attack
Remission Prophylactic Treatment
Global Neuromyelitis Optic Spectrum Disorder Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (Kiloton)
Global Neuromyelitis Optic Spectrum Disorder Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neuromyelitis Optic Spectrum Disorder Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Neuromyelitis Optic Spectrum Disorder Drugs revenues share in global market, 2022 (%)
Key companies Neuromyelitis Optic Spectrum Disorder Drugs sales in global market, 2018-2023 (Estimated), (Kiloton)
Key companies Neuromyelitis Optic Spectrum Disorder Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neuromyelitis Optic Spectrum Disorder Drugs, market overview.
Chapter 2: Global Neuromyelitis Optic Spectrum Disorder Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Neuromyelitis Optic Spectrum Disorder Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neuromyelitis Optic Spectrum Disorder Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Neuromyelitis Optic Spectrum Disorder Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Neuromyelitis Optic Spectrum Disorder Drugs Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
75 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Neuromyelitis Optic Spectrum Disorder Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neuromyelitis Optic Spectrum Disorder Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neuromyelitis Optic Spectrum Disorder Drugs Overall Market Size
2.1 Global Neuromyelitis Optic Spectrum Disorder Drugs Market Size: 2022 VS 2030
2.2 Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Neuromyelitis Optic Spectrum Disorder Drugs Sales: 2018-2030
3 Company Landscape
3.1 Top Neuromyelitis Optic Spectrum Disorder Drugs Players in Global Market
3.2 Top Global Neuromyelitis Optic Spectrum Disorder Drugs Companies Ranked by Revenue
3.3 Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Companies
3.4 Global Neuromyelitis Optic Spectrum Disorder Drugs Sales by Companies
3.5 Global Neuromyelitis Optic Spectrum Disorder Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Neuromyelitis Optic Spectrum Disorder Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Neuromyelitis Optic Spectrum Disorder Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Neuromyelitis Optic Spectrum Disorder Drugs Players in Global Market
3.8.1 List of Global Tier 1 Neuromyelitis Optic Spectrum Disorder Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Neuromyelitis Optic Spectrum Disorder Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Market Size Markets, 2022 & 2030
4.1.2 Glucocorticoids
4.1.3 Immunotherapies
4.1.4 Other
4.2 By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue & Forecasts
4.2.1 By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, 2018-2023
4.2.2 By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, 2024-2030
4.2.3 By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share, 2018-2030
4.3 By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales & Forecasts
4.3.1 By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales, 2018-2023
4.3.2 By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales, 2024-2030
4.3.3 By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share, 2018-2030
4.4 By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2022 & 2030
5.1.2 Acute Attack
5.1.3 Remission Prophylactic Treatment
5.2 By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue & Forecasts
5.2.1 By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, 2018-2023
5.2.2 By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, 2024-2030
5.2.3 By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share, 2018-2030
5.3 By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales & Forecasts
5.3.1 By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales, 2018-2023
5.3.2 By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales, 2024-2030
5.3.3 By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share, 2018-2030
5.4 By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2022 & 2030
6.2 By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue & Forecasts
6.2.1 By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, 2018-2023
6.2.2 By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, 2024-2030
6.2.3 By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share, 2018-2030
6.3 By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales & Forecasts
6.3.1 By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales, 2018-2023
6.3.2 By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales, 2024-2030
6.3.3 By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Neuromyelitis Optic Spectrum Disorder Drugs Revenue, 2018-2030
6.4.2 By Country - North America Neuromyelitis Optic Spectrum Disorder Drugs Sales, 2018-2030
6.4.3 US Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.4.4 Canada Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.4.5 Mexico Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Neuromyelitis Optic Spectrum Disorder Drugs Revenue, 2018-2030
6.5.2 By Country - Europe Neuromyelitis Optic Spectrum Disorder Drugs Sales, 2018-2030
6.5.3 Germany Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.5.4 France Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.5.5 U.K. Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.5.6 Italy Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.5.7 Russia Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.5.8 Nordic Countries Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.5.9 Benelux Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Neuromyelitis Optic Spectrum Disorder Drugs Revenue, 2018-2030
6.6.2 By Region - Asia Neuromyelitis Optic Spectrum Disorder Drugs Sales, 2018-2030
6.6.3 China Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.6.4 Japan Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.6.5 South Korea Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.6.6 Southeast Asia Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.6.7 India Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Neuromyelitis Optic Spectrum Disorder Drugs Revenue, 2018-2030
6.7.2 By Country - South America Neuromyelitis Optic Spectrum Disorder Drugs Sales, 2018-2030
6.7.3 Brazil Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.7.4 Argentina Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Neuromyelitis Optic Spectrum Disorder Drugs Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Neuromyelitis Optic Spectrum Disorder Drugs Sales, 2018-2030
6.8.3 Turkey Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.8.4 Israel Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.8.5 Saudi Arabia Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
6.8.6 UAE Neuromyelitis Optic Spectrum Disorder Drugs Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Neuromyelitis Optic Spectrum Disorder Drugs Major Product Offerings
7.1.4 Pfizer Neuromyelitis Optic Spectrum Disorder Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Fresenius
7.2.1 Fresenius Company Summary
7.2.2 Fresenius Business Overview
7.2.3 Fresenius Neuromyelitis Optic Spectrum Disorder Drugs Major Product Offerings
7.2.4 Fresenius Neuromyelitis Optic Spectrum Disorder Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Fresenius Key News & Latest Developments
7.3 Teva
7.3.1 Teva Company Summary
7.3.2 Teva Business Overview
7.3.3 Teva Neuromyelitis Optic Spectrum Disorder Drugs Major Product Offerings
7.3.4 Teva Neuromyelitis Optic Spectrum Disorder Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Teva Key News & Latest Developments
7.4 Sandoz
7.4.1 Sandoz Company Summary
7.4.2 Sandoz Business Overview
7.4.3 Sandoz Neuromyelitis Optic Spectrum Disorder Drugs Major Product Offerings
7.4.4 Sandoz Neuromyelitis Optic Spectrum Disorder Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Sandoz Key News & Latest Developments
7.5 Intas
7.5.1 Intas Company Summary
7.5.2 Intas Business Overview
7.5.3 Intas Neuromyelitis Optic Spectrum Disorder Drugs Major Product Offerings
7.5.4 Intas Neuromyelitis Optic Spectrum Disorder Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Intas Key News & Latest Developments
7.6 Gyjtrs
7.6.1 Gyjtrs Company Summary
7.6.2 Gyjtrs Business Overview
7.6.3 Gyjtrs Neuromyelitis Optic Spectrum Disorder Drugs Major Product Offerings
7.6.4 Gyjtrs Neuromyelitis Optic Spectrum Disorder Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Gyjtrs Key News & Latest Developments
7.7 NANG KUANG
7.7.1 NANG KUANG Company Summary
7.7.2 NANG KUANG Business Overview
7.7.3 NANG KUANG Neuromyelitis Optic Spectrum Disorder Drugs Major Product Offerings
7.7.4 NANG KUANG Neuromyelitis Optic Spectrum Disorder Drugs Sales and Revenue in Global (2018-2023)
7.7.5 NANG KUANG Key News & Latest Developments
7.8 Tianjin Kingyork
7.8.1 Tianjin Kingyork Company Summary
7.8.2 Tianjin Kingyork Business Overview
7.8.3 Tianjin Kingyork Neuromyelitis Optic Spectrum Disorder Drugs Major Product Offerings
7.8.4 Tianjin Kingyork Neuromyelitis Optic Spectrum Disorder Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Tianjin Kingyork Key News & Latest Developments
7.9 Baxter
7.9.1 Baxter Company Summary
7.9.2 Baxter Business Overview
7.9.3 Baxter Neuromyelitis Optic Spectrum Disorder Drugs Major Product Offerings
7.9.4 Baxter Neuromyelitis Optic Spectrum Disorder Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Baxter Key News & Latest Developments
7.10 CSL
7.10.1 CSL Company Summary
7.10.2 CSL Business Overview
7.10.3 CSL Neuromyelitis Optic Spectrum Disorder Drugs Major Product Offerings
7.10.4 CSL Neuromyelitis Optic Spectrum Disorder Drugs Sales and Revenue in Global (2018-2023)
7.10.5 CSL Key News & Latest Developments
7.11 Grifols
7.11.1 Grifols Company Summary
7.11.2 Grifols Neuromyelitis Optic Spectrum Disorder Drugs Business Overview
7.11.3 Grifols Neuromyelitis Optic Spectrum Disorder Drugs Major Product Offerings
7.11.4 Grifols Neuromyelitis Optic Spectrum Disorder Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Grifols Key News & Latest Developments
7.12 Octapharma
7.12.1 Octapharma Company Summary
7.12.2 Octapharma Neuromyelitis Optic Spectrum Disorder Drugs Business Overview
7.12.3 Octapharma Neuromyelitis Optic Spectrum Disorder Drugs Major Product Offerings
7.12.4 Octapharma Neuromyelitis Optic Spectrum Disorder Drugs Sales and Revenue in Global (2018-2023)
7.12.5 Octapharma Key News & Latest Developments
7.13 CBOP
7.13.1 CBOP Company Summary
7.13.2 CBOP Neuromyelitis Optic Spectrum Disorder Drugs Business Overview
7.13.3 CBOP Neuromyelitis Optic Spectrum Disorder Drugs Major Product Offerings
7.13.4 CBOP Neuromyelitis Optic Spectrum Disorder Drugs Sales and Revenue in Global (2018-2023)
7.13.5 CBOP Key News & Latest Developments
8 Global Neuromyelitis Optic Spectrum Disorder Drugs Production Capacity, Analysis
8.1 Global Neuromyelitis Optic Spectrum Disorder Drugs Production Capacity, 2018-2030
8.2 Neuromyelitis Optic Spectrum Disorder Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Neuromyelitis Optic Spectrum Disorder Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Neuromyelitis Optic Spectrum Disorder Drugs Supply Chain Analysis
10.1 Neuromyelitis Optic Spectrum Disorder Drugs Industry Value Chain
10.2 Neuromyelitis Optic Spectrum Disorder Drugs Upstream Market
10.3 Neuromyelitis Optic Spectrum Disorder Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Neuromyelitis Optic Spectrum Disorder Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Neuromyelitis Optic Spectrum Disorder Drugs in Global Market
Table 2. Top Neuromyelitis Optic Spectrum Disorder Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales by Companies, (Kiloton), 2018-2023
Table 6. Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Neuromyelitis Optic Spectrum Disorder Drugs Price (2018-2023) & (US$/Ton)
Table 8. Global Manufacturers Neuromyelitis Optic Spectrum Disorder Drugs Product Type
Table 9. List of Global Tier 1 Neuromyelitis Optic Spectrum Disorder Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neuromyelitis Optic Spectrum Disorder Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue (US$, Mn), 2024-2030
Table 14. By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), 2018-2023
Table 15. By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), 2024-2030
Table 16. By Application ? Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue (US$, Mn), 2024-2030
Table 19. By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), 2018-2023
Table 20. By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), 2024-2030
Table 21. By Region ? Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue (US$, Mn), 2024-2030
Table 24. By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), 2018-2023
Table 25. By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), 2024-2030
Table 26. By Country - North America Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2024-2030
Table 28. By Country - North America Neuromyelitis Optic Spectrum Disorder Drugs Sales, (Kiloton), 2018-2023
Table 29. By Country - North America Neuromyelitis Optic Spectrum Disorder Drugs Sales, (Kiloton), 2024-2030
Table 30. By Country - Europe Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2024-2030
Table 32. By Country - Europe Neuromyelitis Optic Spectrum Disorder Drugs Sales, (Kiloton), 2018-2023
Table 33. By Country - Europe Neuromyelitis Optic Spectrum Disorder Drugs Sales, (Kiloton), 2024-2030
Table 34. By Region - Asia Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2024-2030
Table 36. By Region - Asia Neuromyelitis Optic Spectrum Disorder Drugs Sales, (Kiloton), 2018-2023
Table 37. By Region - Asia Neuromyelitis Optic Spectrum Disorder Drugs Sales, (Kiloton), 2024-2030
Table 38. By Country - South America Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2024-2030
Table 40. By Country - South America Neuromyelitis Optic Spectrum Disorder Drugs Sales, (Kiloton), 2018-2023
Table 41. By Country - South America Neuromyelitis Optic Spectrum Disorder Drugs Sales, (Kiloton), 2024-2030
Table 42. By Country - Middle East & Africa Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2024-2030
Table 44. By Country - Middle East & Africa Neuromyelitis Optic Spectrum Disorder Drugs Sales, (Kiloton), 2018-2023
Table 45. By Country - Middle East & Africa Neuromyelitis Optic Spectrum Disorder Drugs Sales, (Kiloton), 2024-2030
Table 46. Pfizer Company Summary
Table 47. Pfizer Neuromyelitis Optic Spectrum Disorder Drugs Product Offerings
Table 48. Pfizer Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), Revenue (US$, Mn) and Average Price (US$/Ton) (2018-2023)
Table 49. Pfizer Key News & Latest Developments
Table 50. Fresenius Company Summary
Table 51. Fresenius Neuromyelitis Optic Spectrum Disorder Drugs Product Offerings
Table 52. Fresenius Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), Revenue (US$, Mn) and Average Price (US$/Ton) (2018-2023)
Table 53. Fresenius Key News & Latest Developments
Table 54. Teva Company Summary
Table 55. Teva Neuromyelitis Optic Spectrum Disorder Drugs Product Offerings
Table 56. Teva Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), Revenue (US$, Mn) and Average Price (US$/Ton) (2018-2023)
Table 57. Teva Key News & Latest Developments
Table 58. Sandoz Company Summary
Table 59. Sandoz Neuromyelitis Optic Spectrum Disorder Drugs Product Offerings
Table 60. Sandoz Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), Revenue (US$, Mn) and Average Price (US$/Ton) (2018-2023)
Table 61. Sandoz Key News & Latest Developments
Table 62. Intas Company Summary
Table 63. Intas Neuromyelitis Optic Spectrum Disorder Drugs Product Offerings
Table 64. Intas Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), Revenue (US$, Mn) and Average Price (US$/Ton) (2018-2023)
Table 65. Intas Key News & Latest Developments
Table 66. Gyjtrs Company Summary
Table 67. Gyjtrs Neuromyelitis Optic Spectrum Disorder Drugs Product Offerings
Table 68. Gyjtrs Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), Revenue (US$, Mn) and Average Price (US$/Ton) (2018-2023)
Table 69. Gyjtrs Key News & Latest Developments
Table 70. NANG KUANG Company Summary
Table 71. NANG KUANG Neuromyelitis Optic Spectrum Disorder Drugs Product Offerings
Table 72. NANG KUANG Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), Revenue (US$, Mn) and Average Price (US$/Ton) (2018-2023)
Table 73. NANG KUANG Key News & Latest Developments
Table 74. Tianjin Kingyork Company Summary
Table 75. Tianjin Kingyork Neuromyelitis Optic Spectrum Disorder Drugs Product Offerings
Table 76. Tianjin Kingyork Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), Revenue (US$, Mn) and Average Price (US$/Ton) (2018-2023)
Table 77. Tianjin Kingyork Key News & Latest Developments
Table 78. Baxter Company Summary
Table 79. Baxter Neuromyelitis Optic Spectrum Disorder Drugs Product Offerings
Table 80. Baxter Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), Revenue (US$, Mn) and Average Price (US$/Ton) (2018-2023)
Table 81. Baxter Key News & Latest Developments
Table 82. CSL Company Summary
Table 83. CSL Neuromyelitis Optic Spectrum Disorder Drugs Product Offerings
Table 84. CSL Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), Revenue (US$, Mn) and Average Price (US$/Ton) (2018-2023)
Table 85. CSL Key News & Latest Developments
Table 86. Grifols Company Summary
Table 87. Grifols Neuromyelitis Optic Spectrum Disorder Drugs Product Offerings
Table 88. Grifols Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), Revenue (US$, Mn) and Average Price (US$/Ton) (2018-2023)
Table 89. Grifols Key News & Latest Developments
Table 90. Octapharma Company Summary
Table 91. Octapharma Neuromyelitis Optic Spectrum Disorder Drugs Product Offerings
Table 92. Octapharma Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), Revenue (US$, Mn) and Average Price (US$/Ton) (2018-2023)
Table 93. Octapharma Key News & Latest Developments
Table 94. CBOP Company Summary
Table 95. CBOP Neuromyelitis Optic Spectrum Disorder Drugs Product Offerings
Table 96. CBOP Neuromyelitis Optic Spectrum Disorder Drugs Sales (Kiloton), Revenue (US$, Mn) and Average Price (US$/Ton) (2018-2023)
Table 97. CBOP Key News & Latest Developments
Table 98. Neuromyelitis Optic Spectrum Disorder Drugs Production Capacity (Kiloton) of Key Manufacturers in Global Market, 2021-2023 (Kiloton)
Table 99. Global Neuromyelitis Optic Spectrum Disorder Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 100. Global Neuromyelitis Optic Spectrum Disorder Drugs Production by Region, 2018-2023 (Kiloton)
Table 101. Global Neuromyelitis Optic Spectrum Disorder Drugs Production by Region, 2024-2030 (Kiloton)
Table 102. Neuromyelitis Optic Spectrum Disorder Drugs Market Opportunities & Trends in Global Market
Table 103. Neuromyelitis Optic Spectrum Disorder Drugs Market Drivers in Global Market
Table 104. Neuromyelitis Optic Spectrum Disorder Drugs Market Restraints in Global Market
Table 105. Neuromyelitis Optic Spectrum Disorder Drugs Raw Materials
Table 106. Neuromyelitis Optic Spectrum Disorder Drugs Raw Materials Suppliers in Global Market
Table 107. Typical Neuromyelitis Optic Spectrum Disorder Drugs Downstream
Table 108. Neuromyelitis Optic Spectrum Disorder Drugs Downstream Clients in Global Market
Table 109. Neuromyelitis Optic Spectrum Disorder Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Neuromyelitis Optic Spectrum Disorder Drugs Segment by Type in 2022
Figure 2. Neuromyelitis Optic Spectrum Disorder Drugs Segment by Application in 2022
Figure 3. Global Neuromyelitis Optic Spectrum Disorder Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Neuromyelitis Optic Spectrum Disorder Drugs Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, 2018-2030 (US$, Mn)
Figure 7. Neuromyelitis Optic Spectrum Disorder Drugs Sales in Global Market: 2018-2030 (Kiloton)
Figure 8. The Top 3 and 5 Players Market Share by Neuromyelitis Optic Spectrum Disorder Drugs Revenue in 2022
Figure 9. By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 10. By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share, 2018-2030
Figure 11. By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share, 2018-2030
Figure 12. By Type - Global Neuromyelitis Optic Spectrum Disorder Drugs Price (US$/Ton), 2018-2030
Figure 13. By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 14. By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share, 2018-2030
Figure 15. By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share, 2018-2030
Figure 16. By Application - Global Neuromyelitis Optic Spectrum Disorder Drugs Price (US$/Ton), 2018-2030
Figure 17. By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 18. By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share, 2018 VS 2022 VS 2030
Figure 19. By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share, 2018-2030
Figure 20. By Region - Global Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share, 2018-2030
Figure 21. By Country - North America Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share, 2018-2030
Figure 22. By Country - North America Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share, 2018-2030
Figure 23. US Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 24. Canada Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 25. Mexico Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 26. By Country - Europe Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share, 2018-2030
Figure 27. By Country - Europe Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share, 2018-2030
Figure 28. Germany Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 29. France Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 30. U.K. Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 31. Italy Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 32. Russia Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 33. Nordic Countries Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 34. Benelux Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 35. By Region - Asia Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share, 2018-2030
Figure 36. By Region - Asia Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share, 2018-2030
Figure 37. China Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 38. Japan Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 39. South Korea Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 40. Southeast Asia Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 41. India Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - South America Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share, 2018-2030
Figure 43. By Country - South America Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share, 2018-2030
Figure 44. Brazil Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 45. Argentina Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 46. By Country - Middle East & Africa Neuromyelitis Optic Spectrum Disorder Drugs Revenue Market Share, 2018-2030
Figure 47. By Country - Middle East & Africa Neuromyelitis Optic Spectrum Disorder Drugs Sales Market Share, 2018-2030
Figure 48. Turkey Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 49. Israel Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 50. Saudi Arabia Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 51. UAE Neuromyelitis Optic Spectrum Disorder Drugs Revenue, (US$, Mn), 2018-2030
Figure 52. Global Neuromyelitis Optic Spectrum Disorder Drugs Production Capacity (Kiloton), 2018-2030
Figure 53. The Percentage of Production Neuromyelitis Optic Spectrum Disorder Drugs by Region, 2022 VS 2030
Figure 54. Neuromyelitis Optic Spectrum Disorder Drugs Industry Value Chain
Figure 55. Marketing Channels
